Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company’s financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting Aerie's website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 20105726. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 20105726. The telephone replay will be available until November 18, 2014.

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company has commenced two Phase 3 registration trials in the United States for triple-action RhopressaTM, named "Rocket 1" and "Rocket 2," where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, along with a third Phase 3 safety trial, named "Rocket 3," in Canada.

The Company also recently completed a Phase 2b clinical trial for quadruple-action RoclatanTM, which met the primary efficacy endpoint, demonstrating statistical superiority of RoclatanTM to each of its components. RoclatanTM is a fixed-dose combination of RhopressaTM with latanoprost, the market-leading prostaglandin analogue, and if approved has the potential to be the most efficacious IOP-lowering therapy.